Haiju Zhang1,2, Hui Li1, Aamir Shaikh1, Yi Caudle1, Baozhen Yao2, Deling Yin1. 1. Department of Internal Medicine, College of Medicine, East Tennessee State University, Johnson City. 2. Department of Pediatrics, Renmin Hospital of Wuhan University, China.
Abstract
Background: microRNA-23b (miR-23b) is a multiple functional miRNA. We hypothesize that miR-23b plays a role in the pathogenesis of sepsis. Our study investigated the effect of miR-23b on sepsis-induced immunosuppression. Methods: Mice were treated with miR-23b inhibitors by tail vein injection 2 days after cecal ligation puncture (CLP)-induced sepsis. Apoptosis in spleens and apoptotic signals were investigated, and survival was monitored. T-cell immunoreactivities were examined during late sepsis. Nuclear factor κB (NF-κB)-inducing kinase (NIK), tumor necrosis factor (TNF)-receptor associated factor 1 (TRAF1), and X-linked inhibitor of apoptosis protein (XIAP), the putative targets of miR-23b, were identified by a dual-luciferase reporter assay. Results: miR-23b expression is upregulated and sustained during sepsis. The activation of the TLR4/TLR9/p38 MAPK/STAT3 signal pathway contributes to the production of miR-23b in CLP-induced sepsis. miR-23b inhibitor decreased the number of spleen cells positive by terminal deoxynucleotidyl transferase dUTP nick-end labeling and improved survival. miR-23b inhibitor restored the immunoreactivity by alleviating the development of T-cell exhaustion and producing smaller amounts of immunosuppressive interleukin 10 and interleukin 4 during late sepsis. We demonstrated that miR-23b mediated immunosuppression during late sepsis by inhibiting the noncanonical NF-κB signal and promoting the proapoptotic signal pathway by targeting NIK, TRAF1, and XIAP. Conclusions: Inhibition of miR-23b reduces late-sepsis-induced immunosuppression and improves survival. miR-23b might be a target for immunosuppression.
Background: microRNA-23b (miR-23b) is a multiple functional miRNA. We hypothesize that miR-23b plays a role in the pathogenesis of sepsis. Our study investigated the effect of miR-23b on sepsis-induced immunosuppression. Methods:Mice were treated with miR-23b inhibitors by tail vein injection 2 days after cecal ligation puncture (CLP)-induced sepsis. Apoptosis in spleens and apoptotic signals were investigated, and survival was monitored. T-cell immunoreactivities were examined during late sepsis. Nuclear factor κB (NF-κB)-inducing kinase (NIK), tumor necrosis factor (TNF)-receptor associated factor 1 (TRAF1), and X-linked inhibitor of apoptosis protein (XIAP), the putative targets of miR-23b, were identified by a dual-luciferase reporter assay. Results:miR-23b expression is upregulated and sustained during sepsis. The activation of the TLR4/TLR9/p38 MAPK/STAT3 signal pathway contributes to the production of miR-23b in CLP-induced sepsis. miR-23b inhibitor decreased the number of spleen cells positive by terminal deoxynucleotidyl transferase dUTP nick-end labeling and improved survival. miR-23b inhibitor restored the immunoreactivity by alleviating the development of T-cell exhaustion and producing smaller amounts of immunosuppressive interleukin 10 and interleukin 4 during late sepsis. We demonstrated that miR-23b mediated immunosuppression during late sepsis by inhibiting the noncanonical NF-κB signal and promoting the proapoptotic signal pathway by targeting NIK, TRAF1, and XIAP. Conclusions: Inhibition of miR-23b reduces late-sepsis-induced immunosuppression and improves survival. miR-23b might be a target for immunosuppression.
Authors: R S Hotchkiss; K W Tinsley; P E Swanson; R E Schmieg; J J Hui; K C Chang; D F Osborne; B D Freeman; J P Cobb; T G Buchman; I E Karl Journal: J Immunol Date: 2001-06-01 Impact factor: 5.422
Authors: Eduardo Tamayo; Esther Gómez; Juan Bustamante; José I Gómez-Herreras; Rosalba Fonteriz; Felipe Bobillo; Jesús F Bermejo-Martín; Javier Castrodeza; Maria Heredia; Inma Fierro; Francisco Javier Álvarez Journal: J Crit Care Date: 2011-11-10 Impact factor: 3.425
Authors: Carola Ledderose; Yi Bao; Stephan Ledderose; Tobias Woehrle; Maria Heinisch; Linda Yip; Jingping Zhang; Simon C Robson; Nathan I Shapiro; Wolfgang G Junger Journal: J Infect Dis Date: 2015-07-06 Impact factor: 5.226
Authors: Jacqueline Unsinger; Hirotaka Kazama; Jacqueline S McDonough; Thomas S Griffith; Richard S Hotchkiss; Thomas A Ferguson Journal: J Immunol Date: 2010-05-12 Impact factor: 5.422
Authors: Markus Bosmann; Norman F Russkamp; Birgit Strobl; Julian Roewe; Liza Balouzian; Florence Pache; Markus P Radsak; Nico van Rooijen; Firas S Zetoune; J Vidya Sarma; Gabriel Núñez; Mathias Müller; Peter J Murray; Peter A Ward Journal: J Immunol Date: 2014-10-27 Impact factor: 5.422
Authors: Doreen E Wesche-Soldato; Chun-Shiang Chung; Joanne Lomas-Neira; Lesley A Doughty; Stephen H Gregory; Alfred Ayala Journal: Blood Date: 2005-06-07 Impact factor: 22.113
Authors: Hannah Greenfeld; Kaoru Takasaki; Michael J Walsh; Ina Ersing; Katharina Bernhardt; Yijie Ma; Bishi Fu; Camille W Ashbaugh; Jackson Cabo; Sarah B Mollo; Hufeng Zhou; Shitao Li; Benjamin E Gewurz Journal: PLoS Pathog Date: 2015-05-21 Impact factor: 6.823
Authors: Jesús Beltrán-García; Rebeca Osca-Verdegal; Elena Nacher-Sendra; Federico V Pallardó; José Luis García-Giménez Journal: Cells Date: 2020-06-25 Impact factor: 6.600